New nasal spray vaccine aims to stop COVID at the nose
NCT ID NCT06026514
First seen Jan 27, 2026 · Last updated May 16, 2026 · Updated 16 times
Summary
This early-stage trial tested a new COVID-19 vaccine given as a nasal spray. The goal was to see if it is safe and triggers an immune response. 27 healthy adults aged 18 to 50 received two doses. The vaccine uses a weakened virus to deliver a piece of the COVID-19 spike protein.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARS-COV-2 INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins Bloomberg School of Public Health
Baltimore, Maryland, 20215, United States
Conditions
Explore the condition pages connected to this study.